Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting

Respiratory Medicine

Volumn 108, Issue 12, 2014, Pages 1786-1793

  Price, David ^a   Keininger, Dorothy ^b   Costa Scharplatz, Madlaina ^c,f   Mezzi, Karen ^b   Dimova, Maria ^d   Asukai, Yumi ^d   Ställberg, Björn ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharma AB   (Sweden)

^d IQVIA   (United States)

^e UPPSALA UNIVERSITY   (Sweden)

^f MAPI GROUP   (Netherlands)

Author keywords

COPD; Cost effectiveness; Cost minimisation; Costs; Economic evaluation

Indexed keywords

FLUTICASONE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; SALMETEROL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG COMBINATION; GLYCOPYRRONIUM BROMIDE; INDACATEROL; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SALBUTAMOL; SALMETEROL XINAFOATE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE SYSTEM; HUMAN; LOW RISK POPULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIMULATION; SWEDEN; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; FORCED EXPIRATORY VOLUME; MONTE CARLO METHOD; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; FLUTICASONE; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SALMETEROL XINAFOATE; SWEDEN;

EID: 84927692827     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.09.015     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2014.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(2095): 2128.
3. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med 2006; 3(11):e442.
4. Lindberg A, Jonsson AC, Rönmark E, Lundgren R, Larssona LG, Lundbäck B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. Respiration 2005; 72: 471-9.
5. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006; 43(1): 75-80.
6. Yawn BP Optimizing chronic obstructive pulmonary disease management in primary care. South Med J 2011; 104(2): 121-7.
7. Ingebrigtsen TS, Marott JL, Vestbo J, et al. Characteristics of undertreatment in COPD in the general population. Chest 2013; 144(6).
8. Jansson SA, Backman H, Stenling A, Lindberg A, Ronmark E, Lundback B. Health economic costs of COPD in Sweden by disease severity e has it changed during a ten years period? Respir Med 2013; 107(12): 1931-8.
9. National Institute for Helath and Clinical Excellence. Chronic obstructive pulmonary disease: costing report. Implementing NICE guidance. 2011. NICE guideline 101.
10. Pharmacological treatment of COPD. New COPD treatment guidelines from the Swedish Medical Products Agency in 2009. Inf från Läkemedelsv 2009; 20(2).
11. The National Board of Health and Welfare. Statistics database: medicines 2007-2012.
12. Lisspers K, Ställberg B, Janson C. Study report to assess the care for patients with asthma/COPD. Report was an assignment of the central collaboration board in Uppsala-Örebro. Omhändertagande av patienter med kroniskt obstruktiv lungsjukdom. 2007. Available from: URL, http://tinyurl.com/nw396lk.
13. Jones R, Freemantle N, Miravitlles M, Bruselle G, et al. Inappropriate prescriptions following initial COPD diagnosis (P2391). European Respiratory Society Congress; 2013. Available from: URL, https://www.ersnetsecure.org/public/prg-congres.abstract?ww-i-presentation=62109.
14. Jochmann A, Neubauer F, Miedinger D, Torok SS, Chhajed PN, Tamm M, et al. General practitioners' adherence to the COPD GOLD guidelines: baseline data from the Swiss COPD Cohort Study. Swiss Med Wkly 2010; 140(w13053).
15. Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract 2014; 15(42).
16. Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med 2014; 108(5): 729-36.
17. Katz PM, Pegoraro V. The use of corticosteroids in patients affected by chronic obstructive pulmonary disease: epidemiological and economic aspects. Farmeconomia percorsi ter 2009; 10(4): 179-88.
18. Small M, Broomfield S, Higgins V. P185 Quantification and treatment patterns of real-world patients classified by the GOLD 2011 strategy. Thorax 2012; 67:A144-5.
19. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease 5. Cochrane Database Syst Rev 2014; 3. CD010115.
20. Miravitlles M, Sicras A, Crespo C, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines. Ther Adv Resp Dis 2013; 7(3): 139-50.
21. Asche CV, Leader S, Plauschinat C, Raparla C, Yan M, Ye X, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2012: 201-9.
22. Tandvårds- & läkemedelsförmånsverket TLV. Application for pharmaceutical benefits scheme. 2014.
23. Ultibro breezhaler summary of product characteristics. 3-10-2013.
24. Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford, UK: Oxford University Press; 2006.
25. Asukai Y, Baldwin M, Fonseca T, Gray A, Mungapen L, Price D. Improving clinical reality in chronic obstructive pulmonary disease economic modelling: development and validation of a micro-simulation approach. Pharmacoconomics 2013; 31: 151-61.
26. Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J COPD 2013; 8: 501-8.
27. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VKT, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol - fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013: 51-60.
28. Mahler DA, Wire P, Horstman D, Chang CH, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91.
29. Calverley PMA, Anderson JA, Celli Bartolome, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8): 775-89.
30. Pallante J, Bryant H, St Clare M, He E, Banerji D. CSR QVA149A2313. A 26-week treatment, multi-center, randomized, Doubleblind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease [data on file]. 9-7-2012.
31. FASS. Swedish national formulary of drugs. FASS se; 2013. Available from: URL, http://www.fass.se/LIF/home/index.jsp.
32. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B. Costs of COPD in Sweden according to disease severity. Chest 2002 Dec; 122(6): 1994-2002.
33. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002 Sep; 96(9): 700-8.
34. Lindberg A, Larsson LG, Muellerova H, Ronmark E, Lundback B. Up-to-date on mortality in COPD e report from the OLIN study. BMC Pulmonary Med 2012; 12(1).
35. Statistics Sweden. Swedish life tables for 2013. 2014. http://www.scbse/. Available from: URL, http://www.scb.se/.
36. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity Stages? Chest 2006; 130(4): 1117-28.
37. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-94.
38. Gallagher N, Green Y, Henley M, Horton R, Banerji D. CSR CQVA149A2303. A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 ug q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). 2012.
39. Regional prices and fees for South region. Full price list 2014. 2014. https://www.skane.se/sv/Webbplatser/Sodraregionvardsnamnden/PriserAvtal/Regionala-priser-och-ersattningar-for-Sodra-sjukvardsregionen-2014/.